S100A11 and hepatocellular carcinoma: Further studies demonstrated that S100A11 is overexpressed in metastatic hepatoma cells, and S100A11 knockdown decreases hepatoma cells proliferation, migration, invasion and EMT progress by inhibiting AKT and ERK signaling pathways.